Retraction to: Meta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection (2022)

Peer-Reviewed Study · Open Forum Infectious Diseases (Oxford University Press); Hill A et al. (retracted authors) · February 2022

Open Forum Infectious Diseases (Oxford University Press), 2022-02: The journal's retraction of the Hill et al. ivermectin meta-analysis, stating that its largest contributing study had been withdrawn over fraudulent data and that other included studies had additional problems.

Subsequently, we and the authors learned that one of the largest studies on which this analysis was based was withdrawn due to fraudulent data; additional problems have emerged regarding other studies included in the original paper.

Open Forum Infectious Diseases (Oxford University Press), 2022-02: The journal's retraction of the Hill et al. ivermectin meta-analysis, stating that its largest contributing study had been withdrawn over fraudulent data and that other included studies had additional problems. Retraction notice, no study population. The notice records that the meta-analysis was published 6 July 2021, that an Expression of Concern preceded retraction while the authors revised, and that a corrected analysis with trial-quality commentary was published as 'Ivermectin for COVID-19: Addressing Potential Bias and Medical Fraud' (DOI 10.1093/ofid/ofab645, recorded here as IVE-51). Correspondence author Andrew Hill, University of Liverpool. India/Egypt-based trials supplied most of the withdrawn evidence. Study type: other.